Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

vital pharma nordic aps - dexamethasonum natríumfosfat - stungulyf/innrennslislyf, lausn - 4 mg/ml

Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

t.p. whelehan son & co. ltd. - buserelinum acetat - stungulyf, lausn - 0,004 mg/ml

Europäische Union - Isländisch - EMA (European Medicines Agency)

alexion europe sas - eculizumab - blóðrauði, ofsakláði - Ónæmisbælandi lyf - soliris er ætlað í fullorðna og börn fyrir meðferð:paroxysmal nóttu haemoglobinuria (pnh). sönnunargögn klínískum gagn er sýnt í sjúklinga með haemolysis með klínískum einkenni(s) marks um hár sjúkdómur starfsemi, óháð blóðgjöf sögu (sjá kafla 5. Óhefðbundin blóðlýsu uremic (ahus). soliris er ætlað í fullorðnir fyrir meðferð:svarar almenn vöðvaslensfár (gmg) í sjúklingum sem eru anti-asetýlkólíns viðtaka (achr) mótefni-jákvæð (sjá kafla 5. neuromyelitis optica svið röskun (nmosd) í sjúklingum sem eru anti-aquaporin-4 (aqp4) mótefni-jákvæð við köstum auðvitað sjúkdómsins.

Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - alaninum inn; argininum inn; glycinum inn; histidinum inn; isoleucinum inn; leucinum inn; lysinum asetat; methioninum inn; phenylalaninum inn; prolinum inn; serinum inn; taurinum inn; threoninum inn; tryptophanum inn; tyrosinum inn; valinum inn; calcii chloridum; natrii glycerophosphas; magnesii sulfas; kalii chloridum; natrii acetas; zinci sulfas; glucosum; soiae oleum raffinatum; triglycerides medium chain; olivae oleum raffinatum; piscis oleum omega-3 acidis abundans - innrennslislyf, fleyti

Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - alaninum inn; argininum inn; glycinum inn; histidinum inn; isoleucinum inn; leucinum inn; lysinum asetat; methioninum inn; phenylalaninum inn; prolinum inn; serinum inn; taurinum inn; threoninum inn; tryptophanum inn; tyrosinum inn; valinum inn; glucosum; soiae oleum raffinatum; triglycerides medium chain; olivae oleum raffinatum; piscis oleum omega-3 acidis abundans - innrennslislyf, fleyti

Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - glucosum; alaninum inn; argininum inn; glycinum inn; histidinum inn; isoleucinum inn; leucinum inn; methioninum inn; phenylalaninum inn; prolinum inn; serinum inn; taurinum inn; threoninum inn; tryptophanum inn; tyrosinum inn; valinum inn; kalii chloridum; zinci sulfas; soiae oleum raffinatum; triglycerides medium chain; olivae oleum raffinatum; fish oil rich in omega-3 acids; calcii chloridum; lysinum inn; magnesii sulfas; natrii acetas; natrii glycerophosphas - innrennslislyf, fleyti

Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - soya-bean oil refined; glucosum; alaninum inn; arginine; aspartic acid; glutamic acid; glycine; histidinum inn; isoleucinum inn; leucinum inn; lysinum inn; methioninum inn; phenylalaninum inn; proline; serine; threoninum inn; tryptophanum inn; tyrosinum inn; valine; magnesii sulfas; kalii chloridum; sodium acetate trihydrate; natrii glycerophosphas; calcium chloride dihydrate - innrennslislyf, fleyti

Island - Isländisch - LYFJASTOFNUN (Icelandic Medicines Agency)

fresenius kabi ab - soya-bean oil refined; glucosum; alaninum inn; arginine; aspartic acid; glutamic acid; glycine; histidinum inn; isoleucinum inn; leucinum inn; lysinum inn; methioninum inn; phenylalaninum inn; proline; serine; threoninum inn; tryptophanum inn; tyrosinum inn; valine; natrii glycerophosphas; magnesii sulfas; kalii chloridum; sodium acetate trihydrate; calcium chloride dihydrate - innrennslislyf, fleyti

Europäische Union - Isländisch - EMA (European Medicines Agency)

pfizer europe ma eeig  - pegfilgrastim - daufkyrningafæð - Ónæmisörvandi, - lækkun á lengd mæði í tengslum og tíðni hita og mæði í tengslum í fullorðinn sjúklinga með frumudrepandi lyfjameðferð fyrir illkynja (með undantekning langvarandi merg hvítblæði og myelodysplastic heilkennum).

Europäische Union - Isländisch - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Æxlishemjandi lyf - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. sjá nánar í kafla 5 til að fá nánari upplýsingar varðandi húðþéttni vaxtarþáttar viðtaka 2 (her2). vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. nánari upplýsingar um her2 stöðu, sjá kafla 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.